Clinical Trial Update: Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating XELOXIRI-3 in elderly or frail patients with advanced pancreatic adenocarcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• Camptosar (irinotecan)
• Eloxatin (oxaliplatin)
• Xeloda (capecitabine)

Snippet

Sponsor: Centre Hospitalier Universitaire de Besancon | Conditions: Metastatic Pancreatic Adenocarcinoma | Phase 2 | Status: TERMINATED